Physician profile
Patrick Szeto
NPI 1063671949
$1,130.43
in general payments reported to CMS, 2019-2025
20 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $179 · 2021: $80.87 · 2022: $139 · 2023: $156 · 2024: $198 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $374.96 | 2021-2025 | Signia, Interstim |
| Medtronic USA, INC. | $166.10 | 2020 | |
| Davol INC. | $134.56 | 2022-2023 | Arista Ah Flexitip |
| Innovation Technologies INC | $88.24 | 2022-2023 | Irrisept |
| Zyla Life Sciences, INC. | $75.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $31.04 | 2019-2021 | |
| Edwards Lifesciences Corporation | $27.30 | 2024 | Hemosphere |
| Intuitive Surgical, INC. | $25.48 | 2024 | |
| La Jolla Pharmaceutical Company | $22.31 | 2022 | |
| Organogenesis INC. | $21.87 | 2024 | |
| Mauna Kea Technologies, INC. | $21.21 | 2021 | |
| Abbvie INC. | $20.04 | 2025 | |
| Solventum Corporation | $18.67 | 2025 | Prevena, Abthera, V.A.C. Veraflo Cleanse Choice |
| W. L. Gore & Associates, INC. | $16.34 | 2025 | Gore Enform Intraperitoneal Biomaterial |
| Boston Scientific Corporation | $15.44 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.24 | 2021 | |
| Axonics, INC. | $14.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.08 | 2019 | |
| Conmed Corporation | $14.06 | 2019 | |
| Smith+Nephew, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Szeto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.